^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD8 expression

    i
    Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
    Entrez ID:
    925
    Related biomarkers:
    Expression
    Others
    Apply
    Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma (SWOG S1616) (NCT03033576)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    10/23/2017
    Primary completion :
    09/19/2023
    Completion :
    12/12/2024
    CD4
    |
    CD8 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (NCI-2018-00918) (NCT03449108)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    04/27/2018
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • CD8 • CD28 • CD27
    |
    CD8 expression • CD28 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1
    Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (iPREDICT) (NCT05013099)
    Phase 2
    ImaginAb, Inc.
    Recruiting
    Last update posted :
    04/11/2024
    Initiation :
    12/09/2021
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    PD-L1 • KRAS • CD8 • PD-1
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression
    Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer (NCT06325423)
    Phase N/A
    Assiut University
    Not yet recruiting
    Last update posted :
    03/26/2024
    Initiation :
    04/01/2024
    Primary completion :
    06/01/2025
    Completion :
    06/01/2027
    CD8
    |
    CD8 expression
    Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients (COLEMAN) (NCT05029791)
    Phase N/A
    Hospices Civils de Lyon
    Recruiting
    Last update posted :
    12/15/2023
    Initiation :
    08/18/2022
    Primary completion :
    11/18/2031
    Completion :
    11/18/2031
    CD8 • ZEB1
    |
    CD8 expression • ZEB1 expression
    Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (S1607) (NCT02965716)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    12/08/2023
    Initiation :
    06/05/2018
    Primary completion :
    06/30/2023
    Completion :
    11/05/2024
    TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86
    |
    CD8 expression
    |
    Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)
    Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL (NCT03559413)
    Phase 1/2
    University Children's Hospital Tuebingen
    Completed
    Last update posted :
    12/04/2023
    Initiation :
    06/01/2016
    Primary completion :
    03/01/2022
    Completion :
    12/01/2023
    CD8 • CD4
    |
    CD8 expression • CD4 expression
    |
    Zyclara (imiquimod)
    Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer (NCT05483075)
    Phase N/A
    NYU Langone Health
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    11/15/2022
    Primary completion :
    03/01/2024
    Completion :
    09/01/2024
    CD8 • GZMB
    |
    CD8 expression • CD8 positive
    SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer (NCT04977024)
    Phase 2
    GeoVax, Inc.
    Recruiting
    Last update posted :
    11/06/2023
    Initiation :
    09/27/2021
    Primary completion :
    03/31/2025
    Completion :
    03/31/2026
    CD8 • PD-1 • IFNG • CD4 • TNFRSF9 • ACE2
    |
    CD8 expression
    Innate T Cells and TKI Discontinuation (TIBIOP-LMC) (NCT04645706)
    Phase N/A
    Poitiers University Hospital
    Active, not recruiting
    Last update posted :
    08/04/2023
    Initiation :
    04/20/2021
    Primary completion :
    04/01/2028
    Completion :
    04/01/2028
    CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20
    |
    CD8 expression • IFNG expression
    Deciphering Mechanisms Underlying Cancer Immunogenicity (DECIDE) (NCT03958240)
    Phase N/A
    Institut Claudius Regaud
    Recruiting
    Last update posted :
    07/24/2023
    Initiation :
    01/17/2020
    Primary completion :
    09/01/2029
    Completion :
    09/01/2029
    PD-1 • CD4
    |
    CD8 expression